Ultragenyx's Genglycos Is the First Gene Therapy for GSDIa

Update September 24, 2026: The September 19 UX111 decision referenced below resolved — approved September 17 as Fayuvi, the first-ever treatment for Sanfilippo syndrome type A.

The FDA granted accelerated approval on August 19 to Ultragenyx’s (RARE) Genglycos (pariglasgene brecaparvovec), the first gene therapy for glycogen storage disease type Ia (GSDIa). The AAV8 therapy delivers a working copy of the G6Pase gene to restore glucose release from the liver, and it is approved for adults and children eight and older. It is given as a one-time intravenous infusion. The decision came four days ahead of the August 23 PDUFA date, and Ultragenyx earned a priority review voucher with it. Shares closed at $25.32 on August 20.

GSDIa is an ultra-rare metabolic disorder affecting 1,500 to 2,500 people in the US and 6,000 to 8,000 worldwide. It is caused by a G6Pase deficiency that prevents the liver from releasing glucose during fasting, leaving patients at risk of severe hypoglycemia, seizures, and even death between meals. Standard care is a burdensome around-the-clock raw cornstarch regimen that still leaves patients with large glucose swings. Families describe waking through the night to dose cornstarch and the constant fear that a missed dose could trigger life-threatening low blood sugar. The Phase 3 GlucoGene study randomized 46 patients to Genglycos or placebo for 48 weeks; treated patients showed a significant reduction in daily cornstarch requirements (p<0.001).

This is Ultragenyx’s first gene therapy approval and fifth FDA approval overall, and it validates the AAV8 liver-targeting approach the company has built its rare-disease platform around. The FDA granted Genglycos regenerative medicine advanced therapy (RMAT) and Fast Track designations, reflecting the unmet need in a disease with no therapy addressing its underlying cause. The drug is manufactured at Ultragenyx’s own facility in Bedford, Massachusetts, which matters because scaling gene therapy production has historically been the bottleneck for rare-disease launches.

The accelerated approval means continued marketing depends on confirmatory data: Ultragenyx will supply two years of safety and efficacy data from 50 commercially treated patients and 20 controls through its Disease Monitoring Program, which will follow patients for up to 10 years. For how gene therapies price and what a one-time multimillion-dollar cure means for payers, see the gene therapy pricing guide, and for AAV versus lentivirus delivery, the AAV vs lentivirus vector explainer. The priority review voucher itself is a tradeable asset worth $100 million or more, as explained in the PRV guide.

What to watch next: the post-marketing confirmatory data. Ultragenyx must verify clinical benefit to keep the drug on the market, the same burden every accelerated gene therapy approval carries.

What It Means for the Trade

The approval itself was well-telegraphed — four days early, but the PDUFA was already on the calendar — so the $25.32 close reflects a franchise already repriced. What the decision actually delivers is twofold: the first gene therapy approval for Ultragenyx (fifth FDA approval overall), and a priority review voucher, a tradeable asset worth $100 million or more that functions as unrestricted funding for the pipeline. In ultra-rare disease, PRVs are real money — Ultragenyx has monetized them before.

The commercial sizing deserves honesty. GSDIa has 1,500 to 2,500 US patients and 6,000 to 8,000 worldwide; even at a gene-therapy price point, this is a low-hundreds-of-millions product at maturity, not a franchise-transformer. The value is strategic: it validates the AAV8 liver platform the company is betting on across its rare-disease portfolio and demonstrates an in-house manufacturing capability (Bedford, Massachusetts) at a moment when most gene-therapy launches have died on CMC, not efficacy.

Mechanism and Market Context

The mechanism is well-matched to the disease. GSDIa is a liver-enzyme deficiency — G6Pase — that blocks glucose release during fasting; an AAV8 vector tropic for hepatocytes delivers a working G6Pase copy exactly where it is needed, as a one-time IV infusion. The Phase 3 GlucoGene trial randomized 46 patients over 48 weeks and hit a significant reduction in daily cornstarch requirements (p<0.001) — cornstarch being the burdensome around-the-clock regimen families use to prevent hypoglycemia. Note what the endpoint measures: reduction in a dietary burden, not hypoglycemia elimination. That is a meaningful, approvable endpoint, but the label’s commercial story is quality-of-life, not cure.

The age cut-off matters commercially: approval covers patients eight and older, leaving the youngest and most fragile patients — arguably the highest-need group — outside the label pending more data. The two-year confirmatory program (50 commercially treated patients, 20 controls, monitoring for up to 10 years) is the standard accelerated-approval trade: marketing now, verification under threat of withdrawal later.

Risks and What Could Go Wrong

1. Confirmatory verification. Accelerated approvals carry a removal clause; if the 50-patient commercial cohort does not confirm benefit, the drug comes off the market.
2. Patient identification and uptake. Ultra-rare metabolic diseases have diagnosed populations that dwarf the undiagnosed pool; gene-therapy uptake requires families to accept a one-time irreversible intervention for a disease they manage today.
3. AAV durability and redosing. AAV8 expression can wane over years, and pre-existing immunity blocks redosing; the 10-year monitoring program exists because nobody knows the long tail.
4. Company context. This approval landed days before the apazunersen Aspire failure wiped out the pipeline story; Genglycos revenue growth is now weighed against a sharply reduced late-stage pipeline.

A clean win in a small indication — own Ultragenyx for the platform and the September 19 UX111 decision, not for this label alone.

Source: Phase 3 GlucoGene study (DTX401) on ClinicalTrials.gov (NCT05139316); Ultragenyx Phase 3 DTX401 announcement